FIELD: medicine; pharmaceuticals and oncology.
SUBSTANCE: invention is related to isopropyl ether 5,6-dimethoxy-γ-oxobenzo[b]thiophene-2-butanoic acid of formula I, which stimulates production of human interferon-beta and has antiproliferative activity mediated by human immune cells, induction of interferon beta gene activity, activation of the STING signalling pathway. A method for preparing compound I by reacting 5,6-dimethoxy-γ-oxobenzo[b]thiophene-2-butanoic acid with anhydrous isopropyl alcohol and thionyl chloride, allowing to obtain the target compound with a yield of 85-94%, is also disclosed.
EFFECT: chemical compound and a method of its preparation are proposed.
3 cl, 3 dwg, 2 ex
I
| Title | Year | Author | Number |
|---|---|---|---|
| BIOMEDICAL CELL PRODUCT WITH SPECIFIC ANTITUMOR ACTIVITY, REPRESENTED BY POPULATIONS OF LYMPHOKINE-ACTIVATED KILLERS AND ANTI-HER2 CAR-γδΤ-OIL AND ANTI-HER2 CAR-T-NK | 2022 |
|
RU2786210C1 |
| PHARMACEUTICAL COMPOSITION EXHIBITING CYTOTOXICITY TOWARDS HUMAN COLON CARCINOMA CELLS | 2020 |
|
RU2747147C1 |
| LOW-TOXICITY PHARMACEUTICAL COMPOSITION WITH ANTICANCER ACTIVITY AGAINST CHOLANGIOCARCINOMA | 2023 |
|
RU2825942C1 |
| PHARMACEUTICAL COMPOSITION EXHIBITING CYTOTOXIC EFFECT ON HUMAN BLADDER CANCER CELLS | 2018 |
|
RU2693378C1 |
| HYDROXAMIC ACIDS, 4-AMINOQUINAZOLINE DERIVATIVES WITH ANTITUMOR ACTIVITY | 2022 |
|
RU2802463C1 |
| METHOD FOR PRODUCTION OF THE RECOMBINANT HUMAN PROTEIN GAGE1 | 2016 |
|
RU2652890C1 |
| AGONISTS OF STING INTERFERON GENE STIMULATOR | 2019 |
|
RU2809022C2 |
| AGENT FOR CANCER PROPHYLAXIS | 2002 |
|
RU2219935C1 |
| CANCER PREVENTING AGENT | 1999 |
|
RU2159109C1 |
| COMBINATIONS (COMPOSITIONS), INCLUDING DMXAA FOR CANCER TREATMENT | 2006 |
|
RU2404764C2 |
